Interferon Beta-1a (AVONEX(®)) as a Treatment Option for Untreated Patients with Multiple Sclerosis (AXIOM): A Prospective, Observational Study

The efficacy and safety of first-line disease-modifying therapies (DMT) for relapsing-remitting multiple sclerosis (RRMS) has been demonstrated in pivotal, randomized trials, but these studies do not reflect the routine care setting where treatment gaps or switches are common. The Avonex as Treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinschnitz, Christoph, Niemczyk, Gabriele, Rehberg-Weber, Karin, Wernsdörfer, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519899/
https://www.ncbi.nlm.nih.gov/pubmed/26154767
http://dx.doi.org/10.3390/ijms160715271

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4519899/
https://www.ncbi.nlm.nih.gov/pubmed/26154767
http://dx.doi.org/10.3390/ijms160715271

Ejemplares similares